1583. In Vitro Activity of Imipenem/Relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa from Patients in ICUs in the Asia/Pacific region – SMART 2015-2018

BACKGROUND: Relebactam (REL) is an inhibitor of class A and C β-lactamases approved in the USA in combination with imipenem (IMI) and cilastatin for the treatment of complicated intraabdominal and urinary tract infections. Elevated antimicrobial resistance rates have been reported in ICUs. Using iso...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Hackel, Meredith, Chen, Wei-Ting, Khoo, Yivonne, Balwani, Kanchan, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778147/
http://dx.doi.org/10.1093/ofid/ofaa439.1763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778147/
http://dx.doi.org/10.1093/ofid/ofaa439.1763

Ejemplares similares